Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB1 | P15086 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 3/20 | 0.47 |
| ▸ | CTSK | P43235 | 3/20 | 0.47 |
| ▸ | CTSS | P25774 | 2/20 | 0.47 |
| ▸ | CTSL | P07711 | 2/20 | 0.47 |
| ▸ | CASP3 | P42574 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21111184 | 0.86 | CTSK (0.57) | CTSBCTSKCTSSCTSLCASP3 | |
| SCHEMBL14337553 | 0.85 | CASP3 (0.53) | ALDH1A1GAACTSBCTSKCTSS | |
| SCHEMBL13043811 | 0.85 | CASP3 (0.53) | ALDH1A1GAACTSBCTSKCTSS | |
| SCHEMBL21110423 | 0.83 | CTSK (0.56) | CTSBCTSKCTSSCTSLCASP3 | |
| SCHEMBL13043801 | 0.80 | CTSK (0.54) | ALDH1A1GAACTSBCTSKCTSL | |
| SCHEMBL14601914 | 0.80 | CTSK (0.54) | ALDH1A1GAACTSBCTSKCTSL | |
| SCHEMBL6612597 | 0.79 | EPHX1 (0.63) | CPB1ALDH1A1GAACTSBCTSK | |
| SCHEMBL28375938 | 0.78 | CTSB (0.48) | CPB1ALDH1A1GAACTSBCTSK | |
| SCHEMBL19345760 | 0.78 | EPHX1 (0.57) | CPB1ALDH1A1GAACTSBCTSK | |
| SCHEMBL7807139 | 0.77 | GAA (0.44) | CPB1ALDH1A1GAACTSBCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590084-B2 | Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof | BLADE THERAPEUTICS, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-20190194139-A1 | CYCLIC KETO-AMIDE COMPOUNDS AS CALPAIN MODULATORS AND METHODS OF PRODUCTION AND USE THEREOF | BLADE THERAPEUTICS, INC. (US) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194139-A1 | CYCLIC KETO-AMIDE COMPOUNDS AS CALPAIN MODULATORS AND METHODS OF PRODUCTION AND USE THEREOF | CAPN1, CAPN9, CAPN2 | CPB1 944/4885ALDH1A1 3594/4885GAA 1581/4885 |
| US-10590084-B2 | Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof | CAPN1, CAPN9, CAPN2 | CPB1 944/4885ALDH1A1 3594/4885GAA 1581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.